NZ726168A - Topical application for an anti-hsv antibody - Google Patents
Topical application for an anti-hsv antibodyInfo
- Publication number
- NZ726168A NZ726168A NZ726168A NZ72616815A NZ726168A NZ 726168 A NZ726168 A NZ 726168A NZ 726168 A NZ726168 A NZ 726168A NZ 72616815 A NZ72616815 A NZ 72616815A NZ 726168 A NZ726168 A NZ 726168A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hsv
- antibody
- infection
- herpes
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14174174 | 2014-06-26 | ||
| PCT/EP2015/064378 WO2015197763A1 (en) | 2014-06-26 | 2015-06-25 | Topical application for an anti-hsv antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ726168A true NZ726168A (en) | 2022-05-27 |
Family
ID=51032986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ726168A NZ726168A (en) | 2014-06-26 | 2015-06-25 | Topical application for an anti-hsv antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11267871B2 (https=) |
| EP (1) | EP3160997B1 (https=) |
| JP (1) | JP6649284B2 (https=) |
| KR (1) | KR102622280B1 (https=) |
| CN (2) | CN106488931B (https=) |
| AU (1) | AU2015279212B2 (https=) |
| CA (1) | CA2950489C (https=) |
| ES (1) | ES2843277T3 (https=) |
| NZ (1) | NZ726168A (https=) |
| RU (1) | RU2703903C2 (https=) |
| SG (1) | SG11201610320RA (https=) |
| WO (1) | WO2015197763A1 (https=) |
| ZA (1) | ZA201607813B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3055555A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgf.beta.1-binding immunoglobulins and use thereof |
| EP3566749A4 (en) * | 2017-01-09 | 2020-09-23 | Medshine Discovery Inc. | THIAZOLE DERIVATIVE AND USES OF IT |
| US11472867B2 (en) | 2017-08-30 | 2022-10-18 | Km Biologics Co., Ltd. | Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof |
| US12247066B2 (en) | 2018-08-28 | 2025-03-11 | Pontificia Universídad Católica de Chile | Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2 |
| WO2020041911A1 (es) * | 2018-08-28 | 2020-03-05 | Pontificia Universidad Catolica De Chile | Anticuerpo monoclonal 11b2c7 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2 |
| EP3941524A1 (en) * | 2019-03-19 | 2022-01-26 | Albert Einstein College of Medicine | Monoclonal antibodies for prevention and treatment of herpes simplex viral infections |
| WO2022002802A1 (en) * | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | HSV gEgI HETERODIMER ANTIBODIES |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20260001939A1 (en) * | 2022-03-02 | 2026-01-01 | Heidelberg Immunotherapeutics Gmbh | Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody |
| TW202426053A (zh) * | 2022-09-02 | 2024-07-01 | 聯合生物製藥股份有限公司 | 單純皰疹病毒感染的治療 |
| EP4727967A1 (en) | 2023-06-16 | 2026-04-22 | Heidelberg ImmunoTherapeutics GmbH | Novel anti-hsv antibody |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018634A1 (en) * | 1994-01-04 | 1995-07-13 | The Scripps Research Institute | Human monoclonal antibodies to herpes simplex virus and methods therefor |
| EP1222281B1 (en) * | 1999-09-30 | 2006-11-15 | University of Washington | Immunoligically significant herpes simplex virus antigens |
| EA013564B1 (ru) * | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| US20070274997A1 (en) | 2003-07-25 | 2007-11-29 | Anthony Simmons | Compositions and Methods for Herpes Simplex Prophylaxis and Treatment |
| US6984492B2 (en) * | 2003-09-05 | 2006-01-10 | Talecris Biotherapeutics, Inc. | Methods and compositions for treating herpes infections |
| WO2010129033A2 (en) | 2009-04-29 | 2010-11-11 | Calmune Corporation | Modified antibodies for passive immunotherapy |
| PL2248825T3 (pl) * | 2009-05-04 | 2013-04-30 | Ribovax Biotechnologies Sa | Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu |
| EP2308895A1 (en) * | 2009-10-01 | 2011-04-13 | Universität Duisburg-Essen | Anti-HSV antibody |
| EP2694542A4 (en) * | 2011-04-08 | 2014-10-08 | Univ Duke | HERPES SIMPLEX VIRUS |
-
2015
- 2015-06-25 NZ NZ726168A patent/NZ726168A/en unknown
- 2015-06-25 SG SG11201610320RA patent/SG11201610320RA/en unknown
- 2015-06-25 CN CN201580034015.2A patent/CN106488931B/zh active Active
- 2015-06-25 CA CA2950489A patent/CA2950489C/en active Active
- 2015-06-25 CN CN202210007608.1A patent/CN114306596A/zh active Pending
- 2015-06-25 RU RU2017102387A patent/RU2703903C2/ru active
- 2015-06-25 WO PCT/EP2015/064378 patent/WO2015197763A1/en not_active Ceased
- 2015-06-25 AU AU2015279212A patent/AU2015279212B2/en active Active
- 2015-06-25 US US15/320,501 patent/US11267871B2/en active Active
- 2015-06-25 EP EP15733409.5A patent/EP3160997B1/en active Active
- 2015-06-25 KR KR1020177000526A patent/KR102622280B1/ko active Active
- 2015-06-25 JP JP2016575171A patent/JP6649284B2/ja active Active
- 2015-06-25 ES ES15733409T patent/ES2843277T3/es active Active
-
2016
- 2016-11-11 ZA ZA2016/07813A patent/ZA201607813B/en unknown
-
2022
- 2022-02-18 US US17/675,329 patent/US20220169705A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017102387A (ru) | 2018-07-26 |
| CN106488931B (zh) | 2021-12-28 |
| US20220169705A1 (en) | 2022-06-02 |
| EP3160997A1 (en) | 2017-05-03 |
| JP6649284B2 (ja) | 2020-02-19 |
| RU2017102387A3 (https=) | 2018-07-26 |
| WO2015197763A1 (en) | 2015-12-30 |
| EP3160997B1 (en) | 2020-10-28 |
| CN106488931A (zh) | 2017-03-08 |
| JP2017520572A (ja) | 2017-07-27 |
| KR102622280B1 (ko) | 2024-01-08 |
| ES2843277T3 (es) | 2021-07-16 |
| AU2015279212A2 (en) | 2017-04-27 |
| CA2950489C (en) | 2022-09-20 |
| CN114306596A (zh) | 2022-04-12 |
| AU2015279212A1 (en) | 2016-12-01 |
| RU2703903C2 (ru) | 2019-10-22 |
| BR112016030422A2 (pt) | 2017-10-24 |
| CA2950489A1 (en) | 2015-12-30 |
| AU2015279212B2 (en) | 2020-08-20 |
| US11267871B2 (en) | 2022-03-08 |
| US20170152304A1 (en) | 2017-06-01 |
| SG11201610320RA (en) | 2017-01-27 |
| KR20170020423A (ko) | 2017-02-22 |
| ZA201607813B (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ726168A (en) | Topical application for an anti-hsv antibody | |
| EP2308895A1 (en) | Anti-HSV antibody | |
| CN108472372B (zh) | 结合不动杆菌的抗体结合剂及其用途 | |
| US10626167B2 (en) | Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2 | |
| US20240083981A1 (en) | Treatment of herpes simplex virus infection | |
| US20260125453A1 (en) | Herpes Zoster Treatment | |
| CN119060193B (zh) | 猴痘病毒双特异抗体及其应用 | |
| JP7748728B2 (ja) | 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用 | |
| EP4474395A1 (en) | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases | |
| EP4727967A1 (en) | Novel anti-hsv antibody | |
| US20250066467A1 (en) | Methods for the treatment of myasthenia gravis | |
| WO2024174020A1 (en) | Herpes zoster treatment | |
| BR112016030422B1 (pt) | Anticorpo anti-hsv e composição farmacêutica compreendendo o referido anticorpo | |
| HK40128668A (zh) | 带状疱疹治疗 | |
| WO2023131262A1 (zh) | 特异性结合SARS-CoV-2的抗原结合蛋白 | |
| CN120289643A (zh) | 一种多特异性抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2024 BY ENVOY Effective date: 20230620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2025 BY ENVOY Effective date: 20240619 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2026 BY CLARIVATE IP SERVICES LIMITED Effective date: 20250604 |